This is a routine shelf update with no immediate capital raise. Monitor for future ATM sales or prospectus supplements that would signal actual dilution. The company's cash position and burn rate from the 10-Q will determine if and when they tap this facility.
Price Chart
Executive Summary
Xilio Therapeutics filed Amendment No. 1 to its S-3 shelf registration, registering up to $250M in securities (common, preferred, debt, units, warrants) including a $14.5M ATM facility with Leerink Partners. The company has already sold $4.6M under the prior S-3 and has a $72.5M net tangible book value as of March 31, 2026. The filing is a routine shelf update to reflect prior sales and updated public float calculations, with no new capital being raised at this time.
Key Financial Metrics
Key Facts
- Shelf registration for up to $250M in securities, including a $14.5M ATM facility with Leerink Partners
- $4.6M already sold under the prior S-3 (File No. 333-285703) prior to this amendment
- Public float calculated at ~$57.6M as of May 26, 2026, limiting primary offerings to 1/3 of float per I.B.6
- Net tangible book value of $72.5M ($12.55/share) as of March 31, 2026
- Pro forma net tangible book value of $72.6M ($3.80/share) including 13.3M prefunded warrants
- Stock price at filing: $8.35/share (May 26, 2026); market cap ~$50M
Financial Impact
No new capital raised; shelf capacity of $250M with $14.5M ATM component; $4.6M already utilized under prior S-3
Risk Factors
- Potential future dilution from ATM sales or other shelf takedowns
- I.B.6 limitation restricts primary offerings to ~$19.2M (1/3 of $57.6M public float) in any 12-month period
- Pre-funded warrants (13.3M shares at $0.0014) represent massive potential dilution if exercised
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-242204 |
| Document: xlo-ex4_4.htm | 0001193125-26-242204 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | Press Release | — | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.30 (−8.29%) |
Aug 12, 2026 10w ago | Press Release | $9.05 $9.41 | ▲ +3.98% | ▲ +4.42% | $8.30 (−8.29%) |
Jun 1, 2026 21w ago | EFFECT | $8.25 $7.70 | ▲ +6.67% | ▲ +3.92% | $8.30 (−0.61%) |
May 27, 2026 21w ago | S-3/A | $8.52 $8.15 | ▼ −4.40% | ▼ −4.35% | $8.30 (−2.58%) |
May 12, 2026 23w ago | 8-K | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.30 (+7.37%) |
May 12, 2026 23w ago | Press Release | $7.73 $8.15 | ▲ +5.43% | ▲ +5.36% | $8.30 (+7.37%) |
Apr 17, 2026 27w ago | Press Release | $8.45 $8.18 | ▼ −3.20% | ▼ −4.11% | $8.30 (−1.78%) |
Apr 16, 2026 27w ago | 3 | $8.57 $8.31 | ▼ −3.03% | ▼ −3.59% | $8.30 (−3.15%) |
Apr 16, 2026 27w ago | 8-K | $8.35 $8.47 | ▲ +1.44% | ▲ +0.45% | $8.30 (−0.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers